June 10, 2010
VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting

FOR IMMEDIATE RELEASE

 

Media Contact:

 

Dan Budwick, Pure Communications

973-271-6085

 

VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting

 

TEL AVIV, Israel, June 10, 2010 – VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company’s lead program, VB-201, at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology. Niva Yacov, M.Sc., project manager at VBL, is scheduled to present a poster entitled “Lecinoxoid in the Treatment of Experimental Rheumatoid Arthritis” on Thursday, June 17, 2010 at 12:00 p.m. CEST in Rome, Italy.

 

VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from VBL’s proprietary Lecinoxoid family that were designed to be orally available, anti-inflammatory medicines. VB-201 has successfully completed four Phase 1 clinical trials involving 120 healthy subjects under a U.S. investigational new drug (IND) application. These Phase 1 trials demonstrated that VB-201 was well tolerated with a favorable safety profile. Preclinical studies indicate that VB-201 has significant potential to treat inflammation in chronic diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and also found to bring about regression of atherosclerosis. VB-201 is currently being evaluated in a Phase 2 efficacy and safety study for the treatment of patients with psoriasis.

 

About VBL Therapeutics

 

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents.VB-201 the lead candidate from this program, has entered Phase 2 clinical development in patients with psoriasis. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, the first dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in 2010. The company was founded in 2000 and is based in Tel Aviv, Israel. VBL has more than 60 granted patents and more than 115 patents pending. For more information on the company, please visit www.vblrx.com.